GGrantIndex
← Search

Developmental Funds

$274,597P30FY2023CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

DEVELOPMENTAL FUNDS ABSTRACT Developmental Funds are an essential component of the UCLA Jonsson Comprehensive Cancer Center (JCCC) total resource package that Center leadership allocates for strategic imperatives to bolster high priority science and support the Center mission of accelerating discoveries to prevent and cure cancer. Use of CCSG Developmental Funds targets priorities identified in the 2019 – 2023 JCCC Strategic Plan, leveraging combinations of additional resources obtained from philanthropy, foundations, UCLA schools and departments, and UCLA Health. Funds deployed for Center development initiatives that originate from the CCSG and other sources support multiple activities that enhance impactful JCCC research in its Los Angeles County catchment area and beyond. These deployments include funds for research faculty recruitment, for innovative transdisciplinary research through the competitive JCCC Intramural Awards Program, and for key initiatives, such as development of interventional early phase clinical research studies in identified high priority areas, or to enhance health care access and reduce disparities for Los Angeles County residents. To maximize the impact that leveraged Developmental Funds have on the Center and the community it serves, the JCCC embraces two overarching specific aims. Aim 1 is to support cutting-edge cancer research as prioritized by the 2019 – 2023 JCCC Strategic Plan through added resourcing of the competitive JCCC Intramural Awards Program. Supported strategic goals include development of highly innovative interventional early phase clinical studies in multiple tumor types informed through Center community outreach and engagement activities that identify top community needs. Aim 2 is to leverage non-CCSG sources of support to fund additional intramural awards and to support recruitment and retention of faculty in areas elevated by the Center Strategic Plan. Areas identified as priorities include expanding clinical research and increasing inclusion of underserved populations, continuing to strengthen the JCCC Oncology Clinical Trials Network, initiatives focused on obesity and metabolism, translational theranostics, and cancer immunotherapy, as well as a focus on cancer biophysics and device commercialization.

View original record on NIH RePORTER →